We're adding 10 years to healthy human lifespan
Age is the biggest risk factor for the diseases that kill most people.
Deaths per 100,000 people per year, by age (5-year rolling average). United States, 2019. Source: CDC WONDER.
| Cause | Age 30 | Age 40 | Age 50 | Age 60 | Age 70 | Age 80 | Age 84 |
|---|---|---|---|---|---|---|---|
| Heart disease | 8 | 27 | 77 | 197 | 402 | 1,081 | 1,716 |
| Cancer | 8 | 27 | 88 | 277 | 566 | 1,067 | 1,310 |
| Alzheimer’s | <1 | <1 | <1 | 3 | 26 | 242 | 480 |
| Stroke | 1 | 4 | 13 | 31 | 80 | 281 | 469 |
| Chronic lung disease | 1 | 2 | 8 | 47 | 130 | 344 | 461 |
Heart disease, cancer, stroke, chronic lung disease, and Alzheimer’s cause more than half of US deaths. The death rate from each multiplies with every decade of adult life.
Medicine treats them one at a time. Curing every cancer would add about three years to US life expectancy, because the other curves keep climbing.
Treating aging itself could bring all of them down together. Here’s how we’re going after it.
Some cells are easier to replace than to fix. We clear out old or diseased microglia and blood stem cells and put in young ones, grown from reprogrammed stem cells (iPSCs) in our own GMP facility.
Most cells can’t be swapped, so we treat them where they are, with small molecules, gene therapy, and AI-designed proteins aimed at the hallmarks of cellular aging. Our furthest along, a drug designed to improve autophagy (cellular recycling), is in a Phase 1 trial.
AI advances fastest where data is plentiful. Biology’s data is scarce and siloed, so we generate our own on robots run by PyLabRobot, our open-source lab software. With OpenAI, we built a protein model that redesigned two Yamanaka factors. In cells, the new versions drove over 50x more stem cell marker expression than the originals.
When we started, Bay Area lab space was nearly impossible to find, so we built labs out of shipping containers and had experiments running two months later. We still work that way. Anything a vendor would slow down, we bring in-house: cell manufacturing, a vivarium, lab automation, our own software.
Six programs across four modalities.
- AutophagyRTR242
Small molecule · Alzheimer's Disease
Phase 1 - iMGRTR888
Allogeneic cell therapy · CNS Conditions
IND Enabling - iHSCRTR890
Autologous cell therapy · Blood Disorders
IND Enabling - Tissue Reprogramming
Gene therapy · Osteoarthritis, Age-related Hearing Loss
Preclinical - AI-Designed Protein Therapeutics
Protein therapeutic · Aging
Proof of Concept - Chemical Rejuvenation
Small molecules · Aging
Proof of Concept
